Purpose Platelet-derived growth factor receptor (PDGFR) inhibition by reducing tumoral interstitial fluid pressure might increase the efficacy of chemotherapy. Imatinib inhibits PDGFR kinase activity at therapeutically relevant doses. This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities.
Introduction
Tumour progression requires concomitant angiogenesis, through endothelial cell recruitment/proliferation, driven in part by vascular endothelial growth factor (VEGF). The establishment of a supporting pericyte network to stabilise the capillary wall is also required; driven at least in part by platelet-derived growth factor receptor-b (PDGFR-b) signalling [14] . PDGFR-b is expressed in tumoural pericytes, endothelial cells and malignant cells including colon cancer [44] . The binding of its ligands (PGDF-BB) directly promotes tumour growth and stimulates angiogenesis through increasing VEGF expression [5, 24, 35] .
Tumoural blood vessels have sparse pericyte coverage and are functionally leaky leading to an elevation of interstitial fluid pressure (IFP) or tumoural interstitial hypertension (TIH) [38] . TIH may limit drug uptake into tumours through the reduction of the hydrostatic gradient, from capillary to tissues [18] . Modulation of tumoural angiogenesis and TIH may enhance tumoural drug exposure, improving chemotherapy efficacy. As PDGFR-b is intimately involved in tumoural angiogenesis and IFP control, it provides a potential target for modulation of both processes.
Imatinib, through inhibition of PDGFR-b, has significant effects upon tumoural microvasculature. In preclinical models, imatinib exposure has been reported to induce impaired endothelial viability, decreased IFP and thus increases the interstitial transcapillary transport of solutes [34, 42] . It also increases the tumoural uptake and antitumour effects of cytotoxics [30, 33] . Based on these data, imatinib has been combined with cytotoxics in clinical trials [1, 16, 25, 37, 45] .
The combined effect of treatment with PDGF and VEGF inhibitors may further lower tumoural IFP. Preclinical studies have confirmed the cooperative effects of imatinib in combination with VEGF inhibitors, including the anti-VEGF monoclonal antibody bevacizumab [4, 20] .
The treatment of colorectal cancer (CRC) has reached a plateau in efficacy. The most active regimens based on oxaliplatin-5FU (FOLFOX) or irinotecan-5FU with biological agents (bevacizumab or the epidermal growth factor receptor antagonists) result in median survivals greater than 20 months [8, 17] . Therefore, we have investigated the combination of imatinib with mFOLFOX6-bevacizumab in advanced CRC. The aims of this trial were to: (1) define the MTD of dose-escalated imatinib plus full dose mFOLFOX6-bevacizumab, (2) define the toxicity and potential pharmacokinetic (PK) interactions of the combination. An exploratory aim was to evaluate the efficacy of the combination.
Patients and methods
This was a Phase I, dose escalation trial of imatinib plus mFOLFOX6-bevacizumab across four oncology centres within the Cancer Trials Australia consortium (Peter MacCallum Cancer Centre, Austin Health, Royal Melbourne and Western Hospitals).
Eligibility
Eligible patients met the following criteria: (1) histologically confirmed metastatic CRC, fit for first-line chemotherapy combined with bevacizumab, (2) measurable, or evaluable disease (RECIST criteria) [41] , (3) ECOG performance status 0 or 1, (4) adequate organ function: (a) bone marrow: platelets C100 9 10 9 /L, neutrophils C1.5 9 10 9 /L, (b) renal function: creatinine clearance C50 mL/min; (c) hepatic function: serum total bilirubin \1.5 9 upper limit of normal (ULN), alanine aminotransferase/aspartate aminotransferase and alkaline phosphatase (ALP) \2.59 ULN in the absence of liver metastases, or \59 ULN in their presence, (5) life expectancy [12 weeks, (6) written informed consent.
Exclusion criteria (1) Patients with significant metastatic disease volume or rapid disease progression who would be compromised by a delay in commencing chemotherapy (maximum of 3 weeks), (2) other malignant disease, apart from non-melanotic skin cancer or cervical carcinoma in situ, unless the cancer was treated with curative intent over 3 years before enrolment without relapse, (3) medical/psychiatric conditions that compromised the patient's ability to give consent or complete protocol requirements or medical co-morbidities with the potential to be exacerbated by or contra-indicate therapy, (4) prior severe reaction to oxaliplatin, including persistent neuropathy (Grade C 1), (5) prior severe reaction to fluoropyrimidines or known dihydropyrimidine dehydrogenase deficiency, (6) if prior adjuvant therapy, relapse within 6 months of a 5-FU-based regimen or within 12 months of an oxaliplatin-based regimen, (7) last dose of radiotherapy received within 4 weeks before treatment start, excluding palliative radiotherapy, (8) treatment with another investigational agent within 28 days, (9) any unresolved toxicity [NCI-CTC Grade 2 from previous therapy, (10) co-administration of potent cytochrome 3A4/5 inducers or inhibitors, (11) active liver disease or a known diagnosis of HIV, and (12) brain metastases or spinal cord compression.
Institutional Ethics Committee approval was obtained.
Treatment regimen
The total treatment period was defined as 26 weeks, comprising of the 2 phases: Following this 26-week period, patients were followed up as per institutional practice until disease progression or death. Prospectively defined dose reductions and omissions based on haematological and non-haematological toxicities were made for relevant agents.
Patient evaluation

Induction phase
Assessments performed on day-14 included physical examination, performance status, toxicity assessment (NCI-CTC version 3), urine analysis and bloods taken for haematology, biochemistry and tumour markers. On day-7 assessments included toxicity assessment and bloods collected for haematology and biochemistry.
Chemotherapy phase After the completion of 12 chemotherapy cycles, patients were reviewed and offered further treatment as per institutional practice.
Imatinib dose escalation protocol
Patients were enrolled into dose levels (DLs) in cohorts of 3 patients. In the induction phase, imatinib was given continuously from day-14 to day 1, together with bevacizumab on day-14, and continued at the same dose during the chemotherapy phase unless dose reductions were required for toxicity. Three DLs were planned, dose level 1 (DL1) 400 mg, DL2 600 and DL3 800 mg daily, continuously.
Dose escalation procedure
Three patients were initially enrolled into each DL: (1) If there were no dose limiting toxicity (DLT) in 3 patients within a cohort, a further 3 patients were enrolled into the next DL, (2) If 1 of 3 patients experienced a DLT, then 3 additional patients were accrued (total of 6 patients) to that DL, (3) If C2 of 3 patients or C2 of 6 patients experienced a DLT, then the next DL down was declared the maximal tolerated dose (MTD). (4) If DLTs were noted in only 1 of 6 patients, then a further 3 patients were enrolled to the next DL. There was no intra-patient dose escalation.
Dose limiting toxicity definition
DLT was defined within the period of three cycles of imatinib and bevacizumab and two cycles of mFOLFOX6 (i.e. 6 weeks). DLTs were defined as: (1) 
Drug analysis
1. Imatinib and CGP074588 plasma levels determined using HPLC with UV detection at 267 nm. Plasma proteins were precipitated using methanol and the supernatant injected on to a reverse-phase HPLC column (Kromasil-C8 5 lm, 250 9 4.6 mm). Analysis was performed at the Royal Adelaide Hospital, Adelaide, Australia. 2. 5FU plasma-level determination 5FU was extracted from plasma by liquid-liquid extraction (LLE) using Chem-Elute Extube cartridges [3] , subsequent elution was achieved with ethyl acetate:methanol, 95:5. The resulting extract was evaporated under air at 45°C and the residue reconstituted in mobile phase. This was then injected onto a Spherisorb 5 lm ODS2, 4.6 9 250 mm, C18 HPLC column (Waters) fitted with a Nova-Pak-C18 Guard-Pak pre-column (Waters). Separation was achieved on a Waters 2690 HPLC system using isocratic conditions. Detection of 5FU and thymine (internal standard) was at 267 nm. This analysis and that of oxaliplatin was performed at the Peter MacCallum Cancer Centre. 3. Oxaliplatin and ultrafiltrate plasma-level determination Total and unbound platinum was measured in patient plasma and plasma ultrafiltrate respectively, at 2,700°C, using graphite furnace atomic absorption spectrometry (Varian SpectrAA 600Z) at 265.9 nm. Plasma ultrafiltrates were prepared by centrifugation through Centrisart-I units (cut off 20,000 Da, Sartorius). Platinum levels in plasma and plasma ultrafiltrates were quantified using platinum chloride standards prepared in matrix-matched diluent.
Pharmacokinetic parameter derivation
All plasma concentration-time data were analysed using non-compartmental methods with WinNonLin Professional version 5.2. Parameters derived for the respective drugs included the following: (1) Imatinib and metabolite: C ss , AUC 0-24h day-14 and cycle 1 day 1, AUC 0-336h (prechemo, day-14 to Cycle 1 day 1), AUC 336-672h (postchemo, cycle 1 day 1 to day 14), CL/F, CL ss , t . (2) Oxaliplatin: C max , t , AUC 0-24h , AUC 0-? , CL, (3) 5FU: CL, C ss and AUC 0-24h . PK parameters were summarised by the arithmetic mean, standard deviation (SD), coefficient of variation [CV = 100 % (SD/Mean)], and number of observations (N).
Statistical analyses
Performed using SAS software. Demographic, clinical and laboratory baseline data were presented using descriptive statistics. Descriptive statistics were used to describe the treatment received, the number of patients in each DL, details of the DLTs, the best response to treatment [41] , as well the number of patients experiencing AEs. The dose intensity and treatment cycles started for all patients were also summarised. Laboratory data were presented using descriptive statistics. Descriptive statistics included the number of observations (N), mean, SD, median, minimum (Min) and maximum (Max) for quantitative variables and counts and percentages for categorical variables.
Results
Patients
Overall 10 patients were accrued, 3 patients in DL1 (400 mg imatinib) and 7 in DL2 (600 mg). The patient demographics are summarised in Table 1 .
Dose administration and escalation
Dose level 1 comprised of 3 patients who received imatinib 400 mg. No patient in DL1 had experienced a DLT, hence DL2 (imatinib 600 mg) was opened. In total, 7 patients were accrued to DL2, 1 patient had progressive disease during the induction phase and was therefore replaced. Overall 3 of these 7 patients experienced a DLT (febrile neutropenia N = 2 and oral cavity infection with Grade 4 neutropenia N = 1). As prospectively defined in the protocol, the patients who suffered these DLTs had all The number of cycles delivered for each DL is shown in Table 2 . All patients in DL1 completed the 12 planned cycles of imatinib ? mFOLFOX6-bevacizumab. In DL2, 1 patient completed the planned 12 cycles. The reasons for non-completion of the planned therapy in DL2 included the following: repeated episodes of Grade 3 neutropenia, febrile neutropenia, fatigue, (N = 1, respectively), progressive disease (N = 2) and other reasons (N = 1). The dose intensity of imatinib ? mFOLFOX6-bevacizumab during the delivered cycles was in excess of 80 % for both DLs ( Table 2) .
The most common AEs were haematological, predominantly neutropenia, as detailed in Table 3 : over 60 % of patients in both DLs experiencing grade 3 or 4 neutropenia. In DL2, 4 of the 6 evaluable patients had grade 3 and 1 had grade 4 neutropenia. Non-haematological AEs are summarised in Table 4 . These were as expected for the mFOLFOX-bevacizumab regimen. Notably though, 2 of 6 patients in DL2 suffered febrile neutropenia.
Imatinib was interrupted for the following reasons: In DL1 (N = 3): grade 3 neutropenia in 2 patients (on 4 occasions), Grade 3 fatigue in 1 patient (on 2 occasions), non-neutropenic infection (dental abscess) in cycle 1 in 1 patient. In DL2 (N = 7): Grade 3 or 4 neutropenia in 4 pts on 4 occasions and febrile neutropenia in 2 patients; 1 patient in cycle 1 and the other in cycles 1 and 5.
In DL1 and DL2, mFOLFOX6 was interrupted when imatinib was withheld. In addition, one patient in DL1 had developed Grade 3 sensory neuropathy in cycle 9. In DL2, one patient had interruption of bevacizumab due to grade 2 hypertension in cycle 11.
Pharmacokinetics
The pharmacokinetics of oxaliplatin (total and ultrafiltrate), imatinib (parent and metabolite CGP074588) and 5FU in DL1 and DL2 are summarised in Table 5 . There was no statistically significant difference between the pharmacokinetics of oxaliplatin and 5FU between the dose levels.
With regard to imatinib in DL1, there was no difference between the PK parameters from 0-24h on day-14 (prechemotherapy) relative to day 1 (post-chemotherapy). However, this was not the case for patients in DL2, where there was a statistically reduced CL of both parent (6.58 vs. 4.37 L/h, P \ 0.05) and metabolite (39.1 vs. 14.8 L/h, P \ 0.05). This was also manifest by a more prolonged t post-chemotherapy that was only significant for the parent drug: 13.5 versus 19.1h, P \ 0.05.
Steady-state PK of imatinib and its metabolite pre-and post-chemotherapy was assessed by the comparison between AUC 0-336h (pre-chemo: day-14 to cycle 1 day 1), versus AUC 336-672h (post-chemo, cycle 1: day 1 to day 14). There was a trend to higher AUC especially for DL2 postchemotherapy; however, this did not reach statistical significance. Overall, the exposure parameters showed a nonlinear increase with respect to imatinib dose for parent and metabolite. 
Efficacy
The overall best response in the three patients in DL1 was one PR and two SD. In DL2, 5 patents had SD (71.4 %) and two patients had PD (28.6 %). For the entire patient population, the best response was 1 PR (10 %), 7 SD (70 %) and 2 PD.
Discussion
The study reported here was the first attempt to combine continuous dosing of imatinib with full dose mFOLFOX6-bevacizumab in patients with advanced CRC. It was assumed that the imatinib steady-state levels (C ss ) achieved by the two dose levels evaluated would be associated with in vitro inhibition of PDGFR: that is in excess of its IC 50 [6] . In support of this, doses of imatinib of 400 mg or greater were sufficient to induce responses in dermatofibrosarcoma protuberans, a tumour driven by PDGFB [26, 36] . The aims of this trial were thus to (1) define the MTD of dose-escalated imatinib in combination with mFOLFOX6-bevacizumab and (2) define the toxicity and potential PK interactions of the combination. The study demonstrated sufficient safety information to indicate the inability to dose-escalate continuous imatinib: the achieved MTD was well below that of continuous single agent imatinib.
The pharmacokinetic parameters for imatinib were comparable to reported single agent studies [12, 19, 22, 31] . The imatinib C ss observed for DL1 and DL2 was in excess of 0.56 lM: sufficient to substantially inhibit PDGFR signalling assuming that plasma concentration approximated intra-tumour concentrations (IC 50 = 0.1 -1.0 lM) [6] . Similarly, PK parameters for oxaliplatin and 5FU were as for other similar FOLFOX regimens [7, 27, 28] . Thus imatinib appears to have had no impact on the PK of oxaliplatin and 5FU. However, the study did not examine the administration of mFOLFOX6-bevacizumab pre-and post-administration of imatinib to determine this directly.
Interestingly in DL2, there was an increased AUC (and reduced CL) for both imatinib and metabolite from day-14 (pre-chemotherapy) relative to day 1 (post-chemotherapy), (P \ 0.05), respectively (Table 5) . There are 2 possible explanations for this observation. The first, this observation may be the result of steady state not being achieved during the sampling time whereby a 1.5-to three-fold drug accumulation occurs after once-daily dosing from the beginning of dosing till the achievement of steady state [21, 32] . The other explanation may be actual changes with CL over time. The reported CL changes with time have been inconsistent: chronic exposure studies have demonstrated, albeit non-significant trends to increased imatinib CL over a 6-or 12-month chronic exposure [11, 19] , but a smaller study with sampling over 60 days observed a decrease in imatinib CL with time [9] . It must be noted that the study reported here was limited by small patient numbers with sampling limited to 28 days.
The mechanism of a reduced CL of imatinib between pre-and post-chemotherapy at the higher dose examined in DL2 is unclear. Oxaliplatin and 5FU are not hepatically cleared. Imatinib and its metabolite are metabolised predominantly by hepatic CYP3A and excreted by the biliaryfaecal route [23] . A phase I study of a bolus/infusional 5FU regimen with imatinib observed no alterations in the imatinib PK [1] . However, there are no data describing the impact of oxaliplatin or bevacizumab on imatinib PK. Similarly, for oxaliplatin or 5FU on the biliary transporters responsible for imatinib excretion. It is also unclear whether chemotherapy-induced mucosal injury within the gastrointestinal tract may have an impact on the activity of enterocyte CYP3A4 and ABCB1, hence altering the first pass metabolism of imatinib. Similarly, patients in DL2 did not have serum liver biochemistry elevations consistent with disease progression or cytotoxic-induced hepatic injury to account for a change in imatinib handling.
In this study, the most common adverse events were haematological, predominantly neutropenia (Table 3) . The observed toxicity is greater than with mFOLFOX6-bevacizumab alone based on the reported phase III trials in advanced CRC patients [8, 13, 15] . In these studies, the observed rates of combined grade 3-4 neutropenia range from 24-49 % [8, 13, 15] , and Grade 4 alone in 19 % [8] .
The reason for the excess toxicity may reflect the small sample size in each cohort, but patients were not heavily pretreated. The increase in toxicity may reflect the altered imatinib PK described above or a pharmacodynamic interaction. PDGF and VEGF also both have roles in hematopoiesis [2] . Single agent imatinib in gastrointestinal stromal tumour patients was associated with grade 3-4 neutropenia in approximately 7 and 3 % at the 400 and 600 mg dose levels, respectively [10] . There are other studies with imatinib and with crenolanib (CP-868,596 a selective PDGFR inhibitor) combined with chemotherapy that had resulted in unexpected increased toxicity [16, 40, 43, 45] . A phase I/II trial has reported the safety and efficacy of imatinib with oxaliplatin-capecitabine-bevacizumab in 49 patients with untreated CRC. The MTD was capecitabine 850 mg/m 2 bid day 1 to 14, oxaliplatin 100 mg/m 2 and bevacizumab 7.5 mg/kg day 1 of a 21 day cycle with imatinib at 300 mg daily [43] . The MTD represents a 15 and 23 % dose reduction for the cytotoxics, respectively, with the 400 mg continuous dosing of imatinib not deliverable. The most common grade 3-4 toxicities were nonhaematological. The overall response rate was 47 % and median PFS of 11.1 months (95 % CI: 9.5-16) [43] .
A phase II trial in patients with metastatic breast cancer reported on the combination of imatinib with docetaxel as first-line treatment [45] . Initially, patients received imatinib 600 mg daily and docetaxel 30 mg/m 2 weekly for 3 weeks on a 28-day cycle. The imatinib dose was lowered to 400 mg daily due to toxicity. The regimen overall was poorly tolerated, primarily because of gastrointestinal toxicity [45] . A two-arm phase Ib trial treated 48 patients with the potent oral PDGFR inhibitor CP-868,596 (60-100 mg bid) combined with docetaxel (75-100 mg/m 2 ), or with the combination of CP-868,596 (60 mg bid), docetaxel (75 mg/m 2 ) and the VEGFR inhibitor axitinib (5 mg bid). The triplet combination could not be dose escalated due to the increased incidence of mucositis-like AEs with concurrent neutropenia relative to that expected for docetaxel alone [29] .
The overall response rate for the patients evaluated in this current study was less than expected given that these patients were being treated in the first-line setting. This was despite the achieved C ss levels of imatinib known to be associated with PDGFR inhibition and full dose of mFOLFOX6-bevacizumab. The trial's primary endpoint was not radiological response rate and as above the cohort was small in size. For the entire patient population, the response rates were: 1 PR (10 %), 7 SD (70 %). In the randomized phase III trials of patients with untreated metastatic CRC receiving FOLFOX ? bevacizumab, the reported response rates ranged from 38 to 52 % [8, 15, 39] . It is conceivable that better tolerability may have been achieved at a DL-1 level of 300 mg daily of imatinib, whilst retaining possibly effective inhibition of PDGFR. However, data from this study as well as the other combination approaches reviewed above did not lend encouragement to proceed in this direction.
In conclusion, the study reported here was the first attempt to combine escalating doses of continuous imatinib with full dose mFOLFOX6-bevacizumab in patients with previously untreated advanced CRC. The imatinib continuous dosing had achieved C ss levels likely to be sufficient to inhibit PDGFR [6] . The imatinib dose of 400 mg was the MTD in combination with full dose mFOLFOX6-bevacizumab. The study provided sufficient safety information to indicate the inability to dose-escalated imatinib beyond 400 mg.
